Sanofi, Regeneron herald more positive PCSK9 data; Durata wins FDA panel nod;

@FierceBiotech: Investors pump $200M into Intarcia's PhIII for once-yearly diabetes therapy. More | Follow @FierceBiotech

@JohnCFierce: Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option. Article | Follow @JohnCFierce

@DamianFierce: On the way home from ACC14? Catch up on the state of the PCSK9 race with our in-depth feature. Read | Follow @DamianFierce

@EmilyMFierce: Committee finds 'scientific misconduct' in blockbuster stem cell papers. News | Follow @EmilyMFierce

> Sanofi ($SNY) and Regeneron ($REGN) are touting positive results from a Japanese Phase II study of alirocumab, their promising PCSK9 inhibitor. News

> Durata Therapeutics ($DRTX) won an FDA panel recommendation for its antibiotic to treat acute bacterial skin infections. More

> The U.K.'s Tiziana Life Sciences is planning to join the wave of European biotech's going public, setting out plans for a $3.3 million IPO. Article

Medical Device News

@FierceMedDev: Covidien's CFO exercised his stock options near the company's 52 week high. Story | Follow @FierceMedDev

@MarkHFierce: Intuitive Surgical's latest da Vinci surgical robot could help it rebound from a challenging year. More | Follow @MarkHFierce

@MichaelGFierce: Wearable data-storing 'electronic skin' could deliver drugs for epilepsy, Parkinson's. Item | Follow @MichaelGFierce

@EmilyWFierce: New paper from researchers at Harvard sheds light on PMA supplement applications for medical devices. Article | Follow @EmilyWFierce

> IPO emigre Lombard Medical looks to raise $60M in a Nasdaq debut. News

> GE Healthcare unit recalls infant warmer systems in China. More

> China's Dehaier Medical continues its turnaround as revenue falls. Story

Pharma News

@FiercePharma: Gilead's Sovaldi triumph puts major hurt on payers' bottom lines. Story | Follow @FiercePharma

@TracyStaton: RT: Today is the first time in my 10 year data that larger cap biotech is trading at the same PE as US pharma. via @MarkSchoenebaum | Follow @TracyStaton

@EricPFierce: GSK attacks African market with combo of goodwill, R&D and plant projects. More | Follow @EricPFierce

@CarlyHFierce: Donald Trump's Twitter tirade blames vaccines for autism increase. News | Follow @CarlyHFierce

> GSK ditches ovarian cancer plans for Votrient. Article

> It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. Story

> Actavis shells out $100M for Thai generics maker in bid for Southeast Asia growth. More

Biotech Research News

> Committee finds 'scientific misconduct' in blockbuster stem cell papers. News

> Anticancer compound could reverse symptoms of schizophrenia. More

> New molecule could provide relief for autoimmune, inflammatory diseases. Story

> Report: U.S. can do more to support global health R&D. Coverage

> Antioxidant could slow progression of Lou Gehrig's disease, extend lifespan. Article

> NIH opens largest U.S. neuroscience research center. Item

Pharma Manufacturing News

> Bayer will spend $138M to expand its Beijing plant. Story

> GSK sells Indonesia plant even as it boosts commitment there. Article

> Hospira settles investor suit tied to its manufacturing mess-ups. News

> GSK commits $165M toward 5 more plants in Africa. More

> FDA lets Fresenius import saline to help with shortage. Piece

> Regeneron resolves objections to its new Ireland plant. Item

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.